7 Things to Know About Liquid-Liquid CPC Systems

Selecting a preparative liquid-liquid chromatography system for CDMO manufacturing requires more than comparing specifications. The real evaluation begins when you ask whether a system designed for one scale will perform reliably at another, whether the method you develop today will transfer to production tomorrow, and whether the technology addresses the bottlenecks that already constrain your purification workflow. LiLiChro gives you a scalable liquid-liquid chromatography platform designed for exactly this transition.

This guide identifies seven factors that CDMO purification leaders and chromatographers should evaluate when choosing a preparative liquid-liquid chromatography system for pilot-to-industrial scale-up. Each factor connects directly to throughput, recovery, and manufacturing robustness.

Quick guide: 7 factors for evaluating preparative liquid-liquid chromatography systems

How we chose these evaluation criteria for liquid-liquid chromatography systems

Purification teams face a common set of constraints when moving from method development to production. The evaluation criteria here reflect the practical realities of CDMO manufacturing environments where throughput, recovery, and process robustness determine whether a separation method becomes operationally viable.

• Scale-up predictability: Does the system allow method transfer from lab to pilot to production without redeveloping the separation?
• Recovery performance: Can you recover high-value compounds without losses to irreversible adsorption or stationary phase degradation?
• Throughput capacity: Will the system handle the crude volumes and batch sizes your manufacturing schedule requires?
• Operating cost profile: What are the recurring consumable costs, solvent requirements, and maintenance demands?
• Crude feed tolerance: Can the system process complex or crude sample matrices without fouling or performance degradation?
• Method development efficiency: How quickly can you move from screening to a validated method?
• Manufacturing integration: Will the technology fit into existing workflows and regulatory documentation requirements?

LiLiChro: preparative liquid-liquid chromatography system for CDMO manufacturing

LiLiChro offers preparative liquid-liquid chromatography systems engineered specifically for the transition from method development to industrial purification. The platform addresses the core challenge facing CDMO purification teams: developing a method at one scale that performs predictably at another. This becomes operationally important when manufacturing schedules depend on reproducible batch-to-batch performance.

The LiLiChro product line spans from the miniLiLi for method development through the midiLiLi for laboratory preparation to the maxiLiLi and prepLiLi for pilot and industrial-scale purification. This design philosophy means the separation method you validate on the smallest instrument transfers directly to production equipment without requiring method redevelopment.

LiLiChro eliminates the recurring column costs and stationary phase degradation issues that constrain traditional preparative chromatography in pharmaceutical manufacturing. The liquid-liquid partitioning approach avoids irreversible adsorption, which directly affects recovery of high-value APIs, peptides, and complex intermediates.

LiLiChro features

• Linear scale-up architecture: The same separation method transfers from miniLiLi (35 mL cell volume) to prepLiLi (100 L cell volume) based on partition behavior and rotor volume rather than empirical column optimization.
• Support-free separation: Both phases are liquid, eliminating column replacement costs, irreversible adsorption losses, and the fouling issues that affect solid-phase preparative chromatography.
• High stationary phase retention: Greater than 80% retention across the product line supports consistent chromatographic performance and reproducible fraction collection.
• Crude feed tolerance: The liquid stationary phase handles complex matrices, crude extracts, and resinous feedstocks that typically clog or foul packed columns.
• Solvent recovery capability: Industrial CPC platforms can support solvent recycling rates of 85-95%, reducing both operating costs and waste disposal requirements.
• Screening study support: Go/No-go feasibility assessment determines whether your target compound can be effectively purified using CPC before committing to equipment investment.

LiLiChro pros and cons

What makes scale-up predictability critical for CDMO manufacturing?

Scale-up predictability determines whether a purification method validated in R&D will perform reliably at production scale. For CDMO operations, unpredictable scale-up behavior creates costly delays, requires extensive revalidation, and can compromise product recovery at exactly the point where material value becomes highest.

Traditional preparative chromatography often exhibits non-linear scale-up behavior. A method developed on a short analytical column with fine particles may require a different compromise at preparative scale: larger particles, a shorter bed, lower linear velocity, or a higher-pressure system. Each compromise affects something else, and the cumulative effect can make a separation that is scientifically successful become economically unattractive.

Liquid-liquid chromatography systems like those from LiLiChro approach scale-up differently. Because separation depends on partition behavior rather than column geometry or particle size, the method developed at one scale transfers more predictably to larger rotor volumes. LiLiChro's CPC technology supports this linear scale-up logic by maintaining consistent stationary phase retention and separation behavior across the product line.

How does crude feed tolerance affect throughput in pilot-to-industrial operations?

The practical difficulty in CDMO manufacturing is that real samples rarely behave like clean standards. Crude pharmaceutical extracts, fermentation broths, and complex intermediate streams contain components that can block inlet frits, occupy pore volume, or accumulate on stationary phases. These effects become operationally important when each batch contains substantially more mass and solvent.

Solid-phase preparative columns can experience pressure rise from batch to batch as fouling accumulates. When maximum pressure is reached, the typical response is to reduce flow, which increases cycle time. More hours per batch mean fewer batches per day, larger solvent inventories, longer fraction-handling windows, and lower equipment utilization. Column cleaning, repacking, or replacement then affects campaign throughput and cost.

Liquid-liquid chromatography systems avoid these issues because there is no packed bed to foul or degrade. The liquid stationary phase can be renewed, and crude or complex samples that would clog traditional columns can often be processed directly. For CDMO teams working with challenging matrices, this difference in crude feed tolerance translates directly to manufacturing robustness and scheduling reliability.

Why LiLiChro is the leading preparative liquid-liquid chromatography system for CDMO scale-up

LiLiChro delivers what CDMO purification teams require: a technology platform where the method developed on a benchtop instrument transfers to industrial production without requiring redevelopment. This changes the scale-up problem from an empirical, column-dependent exercise into a predictable engineering calculation based on partition behavior and rotor volume.

The LiLiChro platform addresses the interconnected constraints that limit traditional preparative chromatography. High recovery through liquid-liquid partitioning means less loss of high-value compounds. No solid stationary phase means no recurring column costs, no degradation, and no fouling from complex matrices. Linear scale-up means methods validated in R&D remain valid at production scale. These advantages compound as projects move from laboratory screening toward commercial manufacturing.

For CDMO and purification teams evaluating liquid-liquid chromatography, LiLiChro offers a clear pathway from feasibility assessment through method development to industrial implementation. The Screening Study determines whether your target compound and critical impurities show suitable partition behavior, giving you a go/no-go answer before committing to equipment investment. Application notes demonstrate the technology across pharmaceutical, biotech, and natural product purification challenges. Contact LiLiChro to evaluate whether a liquid-liquid approach can address the bottleneck in your current purification workflow.

FAQs about preparative liquid-liquid chromatography systems for CDMO manufacturing

What is the difference between liquid-liquid chromatography and preparative HPLC?

Liquid-liquid chromatography uses two immiscible liquid phases for separation, while preparative HPLC uses a solid stationary phase such as silica. This difference affects recovery, scale-up predictability, and operating costs. LiLiChro liquid-liquid systems eliminate the irreversible adsorption and column degradation issues that can constrain preparative HPLC workflows, making them particularly relevant for high-value APIs and complex intermediates.

How long does it take to develop a CPC method for a new compound?

Method development timelines vary by compound complexity, but LiLiChro's Screening Study typically delivers a go/no-go feasibility assessment and initial chromatogram data in a few days. Full method optimization on the miniLiLi can often be completed in one to two weeks. This compares favorably to the extended timelines sometimes required for optimizing preparative HPLC methods on new compound classes.

Can liquid-liquid chromatography handle crude pharmaceutical extracts?

Yes. Liquid-liquid chromatography systems tolerate crude and complex sample matrices far better than packed-column chromatography. LiLiChro systems can process samples that would typically clog or foul solid-phase columns because there is no packed bed to obstruct. This makes the technology particularly relevant for fermentation-derived compounds, botanical extracts, and intermediate purification steps.

What recovery rates are typical for CPC purification?

LiLiChro liquid-liquid chromatography systems can achieve very high product recovery because there is no solid support where compounds can adsorb irreversibly. The liquid stationary phase can be flushed out after the run, recovering compounds that would otherwise be lost. For high-value pharmaceutical compounds, this recovery advantage directly affects process economics and manufacturing yield.

Is liquid-liquid chromatography suitable for GMP manufacturing?

Yes. Liquid-liquid chromatography can be implemented in GMP manufacturing environments. The technology supports the documentation, process control, and reproducibility requirements of regulated pharmaceutical manufacturing. LiLiChro works with CDMO and pharmaceutical teams to ensure their purification workflows meet applicable regulatory standards.

How does solvent consumption compare between CPC and preparative HPLC?

Industrial CPC platforms like LiLiChro's prepLiLi can support solvent recovery rates of 85-95%, substantially reducing both operating costs and waste disposal requirements compared to traditional preparative chromatography. For CDMO operations facing ESG pressure, regulatory sustainability requirements, or rising solvent disposal costs, this creates both an operational and strategic advantage.